Aloysious Ssemaganda
ID: UNCST-2023-R008046
|
Clinical Performance of i.Mune CD4 diagnostic assay amongst people living with Human immunodeficiency virus (HIV) in Uganda (CPHL-CPSP_001)
REFNo: HS5680ES
The primary objective of this study is to evaluate the clinical performance and validity of the i.Mune CD4 diagnostic assay compared to WHO pre-qualified and CE-marked Abbott PIMA CD4 test using matched liquid and dried venous blood as well as capillary dried blood specimen
collected from people living with HIV in Uganda.
Secondary objectives of this study are:
-To validate the i.Mune CD4 diagnostic assay using the Applied Biosystems™ QuantStudio 5 PCR System in Uganda to support WHO pre-qualification.
-To establish trueness of measurement of the i.Mune CD4 diagnostic assay using the LightCycler 480 Instrument II and the LightCycler PRO in comparison to the reference method (Abbott CD4 PIMA) to support CE-marking of the assay.
|
Uganda |
2025-04-02 8:53:21 |
2028-04-02 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
CAROLYNE OLEO
ID: UNCST-2024-R003845
|
CHARACTERIZATION OF CLINICAL OUTCOMES AMONG AMBULATORY GYNECOLOGY SURGERY RECIPIENTS AT KYABIRWA SURGICAL CENTER, BUDONDO SUB COUNTY, JINJA CITY
REFNo: HS5656ES
3. To disaggregate the clinical outcomes of among ambulatory gynecological surgery recipients at Kyabirwa surgical center, with their characteristics ,2. To develop a typology of the clinical outcomes among ambulatory gynecological surgery recipients at Kyabirwa surgical center, Budondo sub county, Jinja city,1. To classify the clinical outcomes among ambulatory gynecological surgery recipients at Kyabirwa surgical center, Budondo sub county, Jinja city,To characterize the clinical outcomes among ambulatory gynecological surgery recipients at kyabirwa surgical center, Budondo sub county, Jinja city,
|
Uganda |
2025-04-02 8:52:03 |
2028-04-02 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Adoke Yeka
ID: UNCST-2021-R004300
|
Assessing durability of PermaNet Dual and PermaNet 3.0 under field conditions in Northern Uganda.
REFNo: HS5657ES
1. To compare the attrition and physical integrity of PermaNet Dual nets to PermaNet 3.0 nets in multiple locations across Northern Uganda over a three-year period, and to estimate median LLIN survival.
2. To characterize the chemical and entomological attributes of PermaNet 3.0 and PermaNet Dual nets over a period of three years after the mass distribution campaign.
3. To provide insight into the community acceptance of PermaNet Dual relative to PermaNet 3.0, and describe social and behavioural aspects related to net use and net care.
4. To assess the impact of net use and net care practices on the functional survival and insecticidal activity of the LLINs across the districts and across time.
|
Uganda |
2025-04-02 8:50:02 |
2028-04-02 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Stephen Asiimwe
ID: UNCST-2019-R000059
|
Uganda Lung Health Study
REFNo: HS5678ES
To identify individuals at highest risk for COPD early in the disease course and intervention targets for preventing disease progression among young adults.
|
Uganda |
2025-04-02 8:46:08 |
2028-04-02 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
.jpg)
|
Henry Mugerwa
ID: UNCST-2019-R000420
|
A phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises
REFNo: HS5274ES
Primary Objective: To compare the efficacy of 5 mg/kg of crizanlizumab versus placebo, with or without hydroxyurea/hydroxycarbamide, on the annualized rate of VOCs* that are HCPmanaged (including VOCs leading to
management at a health care facility or those managed via remote consultation) over the planned 52-week treatment period in SCD
patients aged 12 years and older with a history of frequent VOCs (4-12 events in 12 months prior to the screening visit).
Secondary Objective: Key secondary objective:
To compare the efficacy of 5 mg/kg of
crizanlizumab versus placebo, with or without
hydroxyurea/hydroxycarbamide, on the
annualized rate of all VOCs including VOCs that are HCP-managed (including VOCs leading to
management at a health care facility or those managed via remote consultation) and VOCs that are self-managed without recommendations from HCP during the event over the planned 52-week treatment period in SCD patients aged 12 years and older with a history of frequent VOCs (4-12 events in the 12 months prior to the screening visit).
To evaluate the annualized rate of VOCs by type of management between treatment arms over the planned 52-week treatment period:
VOCs that are HCP-managed at a health
care facility
• VOCs that are HCP-managed via remote
consultation
• VOCs that are self-managed without
recommendations from HCP during the
event
• VOCs that are HCP-managed via remote
consultation or self-managed without
recommendations from HCP during the
event
• To evaluate the time to first VOC that is HCPmanaged (including VOCs leading to
management at a health care facility or those managed via remote consultation) between treatment arms over the planned 52-week treatment period.
To evaluate the proportion of participants free from VOCs that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) between treatment arms over the planned 52-week treatment period.
To evaluate the duration of VOCs that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) between treatment arms over the planned 52-week treatment period.
To evaluate the safety and immunogenicity of crizanlizumab 5 mg/kg over the 2-year study
period.
To explore the efficacy of crizanlizumab 5 mg/kg over the 2-year study period.
To explore the proportion of VOCs that are selfmanaged without recommendations from HCP during the event, versus VOCs that are HCP-managed (including VOCs leading to
management at a health care facility or those managed via remote consultation) between treatment arms over the planned treatment period of 52 weeks.
To explore the proportion of VOCs that are HCP-managed via remote consultation versus VOCs that are HCP-managed at a healthcare facility between treatment arms over the planned 52-week treatment period.
To explore the incidence rates of all VOCs,
VOCs that are HCP-managed at a healthcare
facility, VOCs that are HCP-managed via remote consultation, VOCs that are HCP-managed,VOCs that are self-managed without
recommendations from HCP during the event,
VOCs that are HCP-managed via remote
consultation or self-managed without
recommendations from HCP during the event, by treatment arm.
To explore quality of life in each treatment arm (ASCQ-Me Short Forms: emotional impact, sleep impact, and joint stiffness).
To explore healthcare facility resource utilization (inpatient hospital admission, emergency room visit, urgent care/clinic visit, infusion center visit)between treatment arms over
the planned 52-week treatment period.
To explore the pharmacokinetics (PK) profile of crizanlizumab at 5 mg/kg.
To explore the pharmacodynamics (PD) (Pselectin inhibition) of crizanlizumab at 5 mg/kg.
To explore biomarkers [p-selectin (free and
total)] and CRP].
To explore exposure-response relationship.
|
Uganda |
2025-04-02 8:43:56 |
2028-04-02 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|